We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Time To Remove Patent Barriers To US Drug Manufacturing

Law360 (August 6, 2018, 12:19 PM EDT) -- We have written a few articles for Law360 about the interplay between patent law and U.S.-based manufacturing of pharmaceuticals.[1] One outstanding issue concerns the role played by patent term extension, pursuant to 35 U.S.C. §156, in determining where to manufacture a generic product. The PTE period is not as restrictive as the regular patent term in several important ways (for example, a compound approved as a pharmaceutical may be able to be manufactured during the PTE for use as a detergent). However, the PTE period currently...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.